- Home
- INAB vs ADXN Comparison
INAB vs ADXN Comparison
Compare INAB & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- ADXN
- Stock Information
- Founded
- INAB 2016
- ADXN 2002
- Country
- INAB United States
- ADXN Switzerland
- Employees
- INAB N/A
- ADXN N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- ADXN Health Care
- Exchange
- INAB Nasdaq
- ADXN Nasdaq
- Market Cap
- INAB 8.7M
- ADXN 8.0M
- IPO Year
- INAB 2021
- ADXN N/A
- Fundamental
- Price
- INAB $2.10
- ADXN $10.70
- Analyst Decision
- INAB Strong Buy
- ADXN Strong Buy
- Analyst Count
- INAB 2
- ADXN 1
- Target Price
- INAB $108.00
- ADXN $30.00
- AVG Volume (30 Days)
- INAB 52.4K
- ADXN 58.4K
- Earning Date
- INAB 11-11-2025
- ADXN 09-01-2025
- Dividend Yield
- INAB N/A
- ADXN N/A
- EPS Growth
- INAB N/A
- ADXN N/A
- EPS
- INAB N/A
- ADXN 0.10
- Revenue
- INAB N/A
- ADXN $278,508.00
- Revenue This Year
- INAB N/A
- ADXN $86.57
- Revenue Next Year
- INAB N/A
- ADXN N/A
- P/E Ratio
- INAB N/A
- ADXN $0.85
- Revenue Growth
- INAB N/A
- ADXN N/A
- 52 Week Low
- INAB $1.91
- ADXN $6.51
- 52 Week High
- INAB $16.70
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- INAB 43.89
- ADXN 78.58
- Support Level
- INAB $1.91
- ADXN $7.70
- Resistance Level
- INAB $2.26
- ADXN $8.21
- Average True Range (ATR)
- INAB 0.11
- ADXN 0.22
- MACD
- INAB -0.01
- ADXN 0.20
- Stochastic Oscillator
- INAB 48.72
- ADXN 68.97
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.